Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Feb 20;16(5):848.
doi: 10.3390/cancers16050848.

Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?

Affiliations
Review

Artificial Intelligence-Based Management of Adult Chronic Myeloid Leukemia: Where Are We and Where Are We Going?

Simona Bernardi et al. Cancers (Basel). .

Abstract

Artificial intelligence (AI) is emerging as a discipline capable of providing significant added value in Medicine, in particular in radiomic, imaging analysis, big dataset analysis, and also for generating virtual cohort of patients. However, in coping with chronic myeloid leukemia (CML), considered an easily managed malignancy after the introduction of TKIs which strongly improved the life expectancy of patients, AI is still in its infancy. Noteworthy, the findings of initial trials are intriguing and encouraging, both in terms of performance and adaptability to different contexts in which AI can be applied. Indeed, the improvement of diagnosis and prognosis by leveraging biochemical, biomolecular, imaging, and clinical data can be crucial for the implementation of the personalized medicine paradigm or the streamlining of procedures and services. In this review, we present the state of the art of AI applications in the field of CML, describing the techniques and objectives, and with a general focus that goes beyond Machine Learning (ML), but instead embraces the wider AI field. The present scooping review spans on publications reported in Pubmed from 2003 to 2023, and resulting by searching "chronic myeloid leukemia" and "artificial intelligence". The time frame reflects the real literature production and was not restricted. We also take the opportunity for discussing the main pitfalls and key points to which AI must respond, especially considering the critical role of the 'human' factor, which remains key in this domain.

Keywords: artificial intelligence; chronic myeloid leukemia; machine learning; minimal residual disease; risk assessment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Graphical report about the number of publications concerning Chronic Myeloid Leukemia and Artificial Intelligence reported in PubMed.
Figure 2
Figure 2
Timeline of clinical trial applying AI in the setting of CML. The trials are divided based on the AI strategies reported. (a) the timeline of publications by year and clustered by technique. The numbers refer to the IDs in the Table 2 (b) An upset plot showing how often the techniques were used. Mostly they have been used alone (the first 4 vertical bars: 9 + 3 + 2 + 2 = 16 times) and only 7 times more than one technique has been used in a paper. Only one paper tested all the four techniques (the last vertical bar, on the right). The horizontal bars show the usage of any cluster.

References

    1. Beam A.L., Kohane I.S. Big Data and Machine Learning in Health Care. JAMA. 2018;319:1317–1318. doi: 10.1001/jama.2017.18391. - DOI - PubMed
    1. Reza Tizhoosh H., Pantanowitz L. Artificial Intelligence and Digital Pathology: Challenges and Opportunities. J. Pathol. Inform. 2018;9:38. doi: 10.4103/jpi.jpi_53_18. - DOI - PMC - PubMed
    1. Zini G., D’Onofrio G. Neural Network in Hematopoietic Malignancies. Clin. Chim. Acta. 2003;333:195–201. doi: 10.1016/S0009-8981(03)00186-4. - DOI - PubMed
    1. Salah H.T., Muhsen I.N., Salama M.E., Owaidah T., Hashmi S.K. Machine Learning Applications in the Diagnosis of Leukemia: Current Trends and Future Directions. Int. J. Lab. Hematol. 2019;41:717–725. doi: 10.1111/ijlh.13089. - DOI - PubMed
    1. Alves R., Gonçalves A.C., Rutella S., Almeida A.M., Las Rivas J.D., Trougakos I.P., Ribeiro A.B.S. Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia—From Molecular Mechanisms to Clinical Relevance. Cancers. 2021;13:4820. doi: 10.3390/cancers13194820. - DOI - PMC - PubMed

LinkOut - more resources